Calcumin (Curcumin)

PreclinicalSmall molecule

Calcumin (Curcumin) is one of 9 small molecule programs targeting Familial adenomatous polyposis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Adenomatous PolyposisActive, not recruiting

Familial Adenomatous PolyposisPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Familial Adenomatous Polyposis

#DrugCompanyPhaseTrials

Rocaltrol

Bayer Aspirin

Actigall

E-Mycin

AAzurity Pharmaceuticals

Approved

2 5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 7

Erapa

RRapamycin Holdings, Inc. dba Emtora Biosciences

Phase 3

1 8

REC-4881

RRecursion Pharmaceuticals Inc.

Phase 2

1 9

Calcumin (Curcumin)

UUniversity of Puerto Rico

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial adenomatous polyposis1 trial

Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)

Completed·UUniversity of Puerto Rico·N/A·NCT00927485·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Calcumin (Curcumin). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Calcumin (Curcumin) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Calcumin (Curcumin). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Puerto Rico company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Puerto Rico

Calcumin (Curcumin)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial adenomatous polyposis1 trial

References

Drug Info

Quick Facts

Related News